TOP 40 HIGH SCHOOL SCIENTISTS IN PRESTIGIOUS REGENERON SCIENCE TALENT SEARCH TO COMPETE FOR $1.8 MILLION IN AWARDS

Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Society for Science (the Society) today announced the top 40 finalists in this year’s Regeneron Science Talent Search, the nation’s oldest and most prestigious science and math competition for high…

Read MoreTOP 40 HIGH SCHOOL SCIENTISTS IN PRESTIGIOUS REGENERON SCIENCE TALENT SEARCH TO COMPETE FOR $1.8 MILLION IN AWARDS

Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

Bristol Myers Squibb (NYSE: BMY) today announced that it has successfully completed its acquisition of Mirati Therapeutics, Inc.® (“Mirati”). With the completion of the acquisition, Mirati shares have ceased trading on…

Read MoreBristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio

Opdivo® in Combination with CABOMETYX® Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Bristol Myers Squibb (NYSE: BMY) and Exelixis, Inc. (NASDAQ: EXEL) today announced four-year follow-up results from the CheckMate -9ER trial evaluating Opdivo® (nivolumab) in combination with CABOMETYX® (cabozantinib) vs. sunitinib in patients with previously untreated advanced…

Read MoreOpdivo® in Combination with CABOMETYX® Demonstrates Long-Term Survival Benefits After Four Years of Follow-Up in the CheckMate -9ER Trial in First-Line Advanced Renal Cell Carcinoma

Sanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Sanofi and Inhibrx, Inc. (“Inhibrx”), a publicly traded clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates, have entered into a definitive agreement under which…

Read MoreSanofi to acquire Inhibrx, Inc., adding potential best-in-class rare disease asset for Alpha-1 Antitrypsin Deficiency to pipeline

Positive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

Akouos, Inc., a wholly owned subsidiary of Eli Lilly and Company (NYSE: LLY), today announced positive initial clinical results from the Phase 1/2 AK-OTOF-101 study, which demonstrated pharmacologic hearing restoration within 30…

Read MorePositive Phase 1/2 Clinical Trial Data for an Investigational Gene Therapy for Genetic Hearing Loss to be Presented at the Association for Research in Otolaryngology 2024 MidWinter Meeting

IMFINZI® plus transarterial chemoembolization and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization

Positive results from the EMERALD-1 Phase III trial showed AstraZeneca’s IMFINZI®(durvalumab) in combination with TACE and bevacizumab demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of…

Read MoreIMFINZI® plus transarterial chemoembolization and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer eligible for embolization